Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: GPI

Gene summary for GPI

Gene summary.

Gene information	Species	Human
	Gene symbol	GPI
	Gene ID	2821
	Gene name	glucose-6-phosphate isomerase
	Gene Alias	AMF
	Cytomap	19q13.11
	Gene Type	protein-coding
	GO ID	GO:0001667
	UniProtAcc	P06744

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2821	GPI	GSM4909281	Human	Breast	IDC	4.43e-03	1.65e-01	0.21
2821	GPI	GSM4909282	Human	Breast	IDC	6.49e-19	4.27e-01	-0.0288
2821	GPI	GSM4909285	Human	Breast	IDC	6.93e-28	4.93e-01	0.21
2821	GPI	GSM4909287	Human	Breast	IDC	6.68e-05	2.48e-01	0.2057
2821	GPI	GSM4909290	Human	Breast	IDC	4.40e-02	1.98e-01	0.2096
2821	GPI	GSM4909291	Human	Breast	IDC	5.14e-07	3.68e-01	0.1753
2821	GPI	GSM4909292	Human	Breast	IDC	1.61e-04	5.87e-01	0.1236
2821	GPI	GSM4909293	Human	Breast	IDC	1.73e-07	2.06e-01	0.1581
2821	GPI	GSM4909304	Human	Breast	IDC	3.23e-07	2.34e-01	0.1636
2821	GPI	GSM4909311	Human	Breast	IDC	7.05e-04	-5.55e-02	0.1534
2821	GPI	GSM4909315	Human	Breast	IDC	1.19e-22	6.25e-01	0.21
2821	GPI	GSM4909317	Human	Breast	IDC	4.20e-11	3.57e-01	0.1355
2821	GPI	GSM4909319	Human	Breast	IDC	2.59e-04	-9.27e-02	0.1563
2821	GPI	brca2	Human	Breast	Precancer	1.27e-03	5.66e-02	-0.024
2821	GPI	brca3	Human	Breast	Precancer	4.46e-09	2.21e-01	-0.0263
2821	GPI	NCCBC5	Human	Breast	DCIS	1.47e-17	6.05e-01	0.2046
2821	GPI	P1	Human	Breast	IDC	9.28e-04	-4.42e-02	0.1527
2821	GPI	P2	Human	Breast	IDC	3.71e-11	5.39e-01	0.21
2821	GPI	DCIS2	Human	Breast	DCIS	8.36e-41	1.25e-01	0.0085
2821	GPI	HTA11_3410_2000001011	Human	Colorectum	AD	3.54e-09	3.86e-01	0.0155

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001931813	Oral cavity	LP	hexose metabolic process	78/4623	237/18723	2.55e-03	1.80e-02	78
GO:004693918	Oral cavity	LP	nucleotide phosphorylation	38/4623	101/18723	2.60e-03	1.83e-02	38
GO:0006163110	Oral cavity	LP	purine nucleotide metabolic process	122/4623	396/18723	3.10e-03	2.11e-02	122
GO:0009150110	Oral cavity	LP	purine ribonucleotide metabolic process	114/4623	368/18723	3.41e-03	2.28e-02	114
GO:190121515	Oral cavity	LP	negative regulation of neuron death	69/4623	208/18723	3.50e-03	2.34e-02	69
GO:000918519	Oral cavity	LP	ribonucleoside diphosphate metabolic process	39/4623	106/18723	3.64e-03	2.42e-02	39
GO:0048872110	Oral cavity	LP	homeostasis of number of cells	87/4623	272/18723	3.75e-03	2.47e-02	87
GO:004603118	Oral cavity	LP	ADP metabolic process	34/4623	90/18723	3.93e-03	2.56e-02	34
GO:001605215	Oral cavity	LP	carbohydrate catabolic process	53/4623	154/18723	4.22e-03	2.70e-02	53
GO:000616518	Oral cavity	LP	nucleoside diphosphate phosphorylation	36/4623	99/18723	6.29e-03	3.71e-02	36
GO:00511561	Oral cavity	LP	glucose 6-phosphate metabolic process	12/4623	24/18723	6.44e-03	3.78e-02	12
GO:000600614	Oral cavity	LP	glucose metabolic process	64/4623	196/18723	7.09e-03	3.98e-02	64
GO:0009135110	Oral cavity	LP	purine nucleoside diphosphate metabolic process	37/4623	103/18723	7.09e-03	3.98e-02	37
GO:0009179110	Oral cavity	LP	purine ribonucleoside diphosphate metabolic process	37/4623	103/18723	7.09e-03	3.98e-02	37
GO:004854528	Skin	AK	response to steroid hormone	73/1910	339/18723	4.51e-10	5.24e-08	73
GO:000170120	Skin	AK	in utero embryonic development	75/1910	367/18723	3.09e-09	2.62e-07	75
GO:005254727	Skin	AK	regulation of peptidase activity	88/1910	461/18723	4.65e-09	3.44e-07	88
GO:004586127	Skin	AK	negative regulation of proteolysis	72/1910	351/18723	5.40e-09	3.90e-07	72
GO:005254827	Skin	AK	regulation of endopeptidase activity	82/1910	432/18723	2.03e-08	1.18e-06	82
GO:001063124	Skin	AK	epithelial cell migration	70/1910	357/18723	5.88e-08	2.95e-06	70

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0001010	Breast	Precancer	Glycolysis / Gluconeogenesis	13/684	67/8465	2.39e-03	1.51e-02	1.16e-02	13
hsa0001013	Breast	Precancer	Glycolysis / Gluconeogenesis	13/684	67/8465	2.39e-03	1.51e-02	1.16e-02	13
hsa01200	Colorectum	AD	Carbon metabolism	55/2092	115/8465	5.53e-08	8.42e-07	5.37e-07	55
hsa00010	Colorectum	AD	Glycolysis / Gluconeogenesis	34/2092	67/8465	3.63e-06	4.34e-05	2.77e-05	34
hsa012001	Colorectum	AD	Carbon metabolism	55/2092	115/8465	5.53e-08	8.42e-07	5.37e-07	55
hsa000101	Colorectum	AD	Glycolysis / Gluconeogenesis	34/2092	67/8465	3.63e-06	4.34e-05	2.77e-05	34
hsa012002	Colorectum	SER	Carbon metabolism	40/1580	115/8465	2.77e-05	3.41e-04	2.47e-04	40
hsa000102	Colorectum	SER	Glycolysis / Gluconeogenesis	24/1580	67/8465	6.62e-04	5.36e-03	3.89e-03	24
hsa012003	Colorectum	SER	Carbon metabolism	40/1580	115/8465	2.77e-05	3.41e-04	2.47e-04	40
hsa000103	Colorectum	SER	Glycolysis / Gluconeogenesis	24/1580	67/8465	6.62e-04	5.36e-03	3.89e-03	24
hsa012004	Colorectum	MSS	Carbon metabolism	43/1875	115/8465	1.37e-04	1.17e-03	7.19e-04	43
hsa000104	Colorectum	MSS	Glycolysis / Gluconeogenesis	28/1875	67/8465	2.36e-04	1.81e-03	1.11e-03	28
hsa012005	Colorectum	MSS	Carbon metabolism	43/1875	115/8465	1.37e-04	1.17e-03	7.19e-04	43
hsa000105	Colorectum	MSS	Glycolysis / Gluconeogenesis	28/1875	67/8465	2.36e-04	1.81e-03	1.11e-03	28
hsa012006	Colorectum	FAP	Carbon metabolism	38/1404	115/8465	1.04e-05	1.44e-04	8.76e-05	38
hsa000106	Colorectum	FAP	Glycolysis / Gluconeogenesis	24/1404	67/8465	1.05e-04	9.46e-04	5.76e-04	24
hsa01250	Colorectum	FAP	Biosynthesis of nucleotide sugars	13/1404	37/8465	4.79e-03	1.91e-02	1.16e-02	13
hsa012007	Colorectum	FAP	Carbon metabolism	38/1404	115/8465	1.04e-05	1.44e-04	8.76e-05	38
hsa000107	Colorectum	FAP	Glycolysis / Gluconeogenesis	24/1404	67/8465	1.05e-04	9.46e-04	5.76e-04	24
hsa012501	Colorectum	FAP	Biosynthesis of nucleotide sugars	13/1404	37/8465	4.79e-03	1.91e-02	1.16e-02	13

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

GPI

SNV

Missense_Mutation

novel

c.1173N>T

p.Trp391Cys

p.W391C

P06744

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.992)

TCGA-AN-A0AK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GPI

SNV

Missense_Mutation

novel

c.781N>G

p.Thr261Ala

p.T261A

P06744

protein_coding

tolerated_low_confidence(1)

benign(0.009)

TCGA-BH-A0B3-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

GPI

SNV

Missense_Mutation

c.1320N>G

p.Phe440Leu

p.F440L

P06744

protein_coding

deleterious_low_confidence(0.01)

probably_damaging(0.999)

TCGA-C8-A26Y-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

GPI

insertion

In_Frame_Ins

novel

c.1640_1641insTTTAAGTTCTGAGATACGTGTGGAGAATGTGCAGGTTTGTTA

p.Thr547_Ser548insLeuSerSerGluIleArgValGluAsnValGlnValCysTyr

p.T547_S548insLSSEIRVENVQVCY

P06744

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

GPI

insertion

Nonsense_Mutation

novel

c.847_848insCCTGGGTGTGTCCGTGTCTGAGGAGGTGGGCCCTGGCACAGGTAT

p.Gly283delinsAlaTrpValCysProCysLeuArgArgTrpAlaLeuAlaGlnValTer

p.G283delinsAWVCPCLRRWALAQV*

P06744

protein_coding

TCGA-AN-A0FX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

GPI

SNV

Missense_Mutation

rs199570323

c.1388N>T

p.Ala463Val

p.A463V

P06744

protein_coding

deleterious_low_confidence(0.02)

possibly_damaging(0.453)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

GPI

SNV

Missense_Mutation

c.355G>T

p.Ala119Ser

p.A119S

P06744

protein_coding

tolerated_low_confidence(0.12)

benign(0.162)

TCGA-HM-A3JK-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

GPI

SNV

Missense_Mutation

rs748408705

c.850C>T

p.Arg284Cys

p.R284C

P06744

protein_coding

deleterious_low_confidence(0)

probably_damaging(1)

TCGA-AA-A022-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

GPI

SNV

Missense_Mutation

c.364N>T

p.Arg122Trp

p.R122W

P06744

protein_coding

deleterious_low_confidence(0.01)

possibly_damaging(0.806)

TCGA-CM-6162-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Chemotherapy

oxaliplatin

GPI

SNV

Missense_Mutation

rs370578920

c.374N>G

p.Asn125Ser

p.N125S

P06744

protein_coding

tolerated_low_confidence(1)

benign(0.003)

TCGA-AG-3887-01

Colorectum

rectum adenocarcinoma

Male

>=65

I/II

Chemotherapy

irinotecan

Page: 1 2 3 4 5 6

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
2821	GPI	ENZYME, GROWTH FACTOR, DRUGGABLE GENOME		6-AN		10884030
2821	GPI	ENZYME, GROWTH FACTOR, DRUGGABLE GENOME		FDG	FLUDEOXYGLUCOSE-F18	10963181
2821	GPI	ENZYME, GROWTH FACTOR, DRUGGABLE GENOME		HEREGULIN		10667603

Page: 1